Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Adapting UK Clinical Practise in Chronic Myeloid Leukaemia in Chronic Phase to Contemporary Management Recommendations: The ADAPT 2.0 Survey.

European journal of haematology - 1 Oct 2026

Milojkovic Dragana, Cross Nicholas C P, Desai Ketul, Frewin Kathryn, Copland Mhairi

Abstract excerpt

OBJECTIVE: Chronic myeloid leukaemia in chronic phase (CML-CP) treatment recommendations have changed substantially in recent years. The ADAPT 2.0 survey aimed to provide an updated understanding of CML-CP management in the UK. METHODS: This healthcare professional (HCP) survey, conducted between December 2023 and June 2024, assessed treatment goals, choice of tyrosine kinase inhibitors (TKIs), unmet needs and...

Read the complete abstract on PubMed

Topics

Humans
United Kingdom
Protein Kinase Inhibitors
Disease Management
Surveys and Questionnaires
Fusion Proteins, bcr-abl

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Practice Guidelines as Topic

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Leukemia, Myeloid, Chronic-Phase

Treatment Outcome

Mutation

Practice Patterns, Physicians'

Source

Open in PubMed Open full text

Identifiers

PMID: 42348343
DOI: 10.1111/ejh.70226
PMCID: PMC13542934

Genes

CP
ABL1
BCR
ELN

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 25 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Adapting UK Clinical Practise in Chronic Myeloid Leukaemia in Chronic Phase to Contemporary Management Recommendations: The ADAPT 2.0 Survey.PMID 42348343Read ↗

Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoringSemantic proximity Read ↗

Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoringSemantic proximity Read ↗

Chronic Myeloid Leukemia, Version 1.2019, NCCN Clinical Practice Guidelines in OncologySemantic proximity Read ↗

Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in OncologySemantic proximity Read ↗

Real-Life Data of Patients with Chronic Myeloid Leukemia in AmazonasSemantic proximity Read ↗

[Guideline of the diagnosis and treatment of chronic myelomonocytic leukemia (2021)].Semantic proximity Read ↗

Real-world data on the use of asciminib in chronic-phase chronic myeloid leukemia after two or more prior tyrosine kinase inhibitors: Results of the Turkish managed access program along with a literature review.Semantic proximity Read ↗

Asciminib (Scemblix): A third-line treatment option for chronic myeloid leukemia in chronic phase with or without T315I mutation.Semantic proximity Read ↗

Chronic lymphocytic leukemia treatment algorithm 2022.Semantic proximity Read ↗

Asciminib monotherapy in patients with chronic-phase chronic myeloid leukemia with the T315I mutation after ≥1 prior tyrosine kinase inhibitor: 2-year follow-up results.Semantic proximity Read ↗

Safety and Efficacy of TKIs in Very Elderly Patients (≥75 Years) with Chronic Myeloid LeukemiaSemantic proximity Read ↗

Update on the use of hydroxyurea for the early management of chronic-phase- chronic myeloid leukemia: data from a real-world cohortSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.